FERRARI, CAMILLA
 Distribuzione geografica
Continente #
NA - Nord America 3.085
EU - Europa 2.262
AS - Asia 629
AF - Africa 6
SA - Sud America 2
Totale 5.984
Nazione #
US - Stati Uniti d'America 3.078
RU - Federazione Russa 1.147
IE - Irlanda 275
IT - Italia 256
PL - Polonia 252
HK - Hong Kong 173
SE - Svezia 173
SG - Singapore 154
CN - Cina 145
IN - India 83
DE - Germania 56
JO - Giordania 47
FI - Finlandia 33
GB - Regno Unito 26
KR - Corea 11
UA - Ucraina 9
VN - Vietnam 8
BE - Belgio 7
CH - Svizzera 7
CA - Canada 5
CI - Costa d'Avorio 5
ES - Italia 5
JP - Giappone 5
CZ - Repubblica Ceca 3
FR - Francia 3
BR - Brasile 2
DK - Danimarca 2
NL - Olanda 2
BG - Bulgaria 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
LT - Lituania 1
MK - Macedonia 1
MX - Messico 1
NG - Nigeria 1
PA - Panama 1
PT - Portogallo 1
TR - Turchia 1
TW - Taiwan 1
Totale 5.984
Città #
Santa Clara 847
Ashburn 410
Dublin 274
Warsaw 252
Fairfield 228
Chandler 217
Singapore 123
Woodbridge 122
Hong Kong 113
Seattle 97
Houston 95
Cambridge 85
Altamura 81
Lawrence 79
Moscow 66
Wilmington 66
Mumbai 60
Ann Arbor 58
Florence 57
Princeton 46
Dearborn 43
Boston 36
Buffalo 34
Bremen 33
Shanghai 31
San Diego 25
Helsinki 23
New York 23
Pune 21
Beijing 20
Medford 18
Kent 16
West Jordan 16
Rome 13
Boardman 12
Los Angeles 11
Seoul 11
Ferrara 9
Brussels 7
Yubileyny 7
Dong Ket 6
Falls Church 6
Lambeth 6
Lappeenranta 6
Norwalk 6
Abidjan 5
Barcelona 5
Guangzhou 5
Misano Adriatico 5
Prato 5
Romola 5
Zhengzhou 5
Genoa 4
Hefei 4
Hillsboro 4
London 4
Milan 4
Toronto 4
Wenzhou 4
Zurich 4
Bern 3
Fiesole 3
Munich 3
Nanjing 3
Prague 3
Santa Maria A Monte 3
Siena 3
Turin 3
Wuhan 3
Afragola 2
Arezzo 2
Bolzano 2
Campi Bisenzio 2
Catania 2
Chicago 2
Codogno 2
Copenhagen 2
Council Bluffs 2
Dallas 2
Jenera 2
Jinan 2
Kilburn 2
Kunming 2
Livorno 2
Menlo Park 2
Monza 2
Nakano 2
Nanchang 2
Pedrengo 2
Phoenix 2
Redwood City 2
Sant'Agata di Militello 2
Shenzhen 2
Tower Hamlets 2
Acton 1
Athens 1
Atlanta 1
Bitola 1
Bologna 1
Bristol 1
Totale 3.965
Nome #
Clinical and neuroimaging profiles to identify C9orf72-FTD patients and serum Neurofilament to monitor the progression and the severity of the disease 296
Low Florbetapir PET Uptake and Normal Aβ1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier 255
"Delirium Day": A nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool 229
Alzheimer's Disease Progression: Factors Influencing Cognitive Decline 146
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study 135
Biomarkers study in atypical dementia: proof of a diagnostic work-up 130
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study 125
Primary Progressive Aphasia: Natural History in an Italian Cohort 122
The Games for Older Adults Active Life (GOAL) project for people with mild cognitive impairment and vascular cognitive impairment: A study protocol for a randomized controlled trial 119
High Frequency of Crossed Aphasia in Dextral in an Italian Cohort of Patients with Logopenic Primary Progressive Aphasia 110
Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy 109
The diagnosis of dementias: a practical tool not to miss rare causes 108
Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia 107
Rethinking on the concept of biomarkers in preclinical Alzheimer’s disease 106
Imaging and Cognitive Reserve Studies Predict Dementia in Presymptomatic Alzheimer's Disease Subjects. 103
Drug prescription and delirium in older inpatients: Results from the nationwide multicenter Italian Delirium Day 2015-2016 101
Novel GRN Mutations in Alzheimer's Disease and Frontotemporal Lobar Degeneration 90
Influence of apoe genotype and clock t3111c interaction with cardiovascular risk factors on the progression to alzheimer’s disease in subjective cognitive decline and mild cognitive impairment patients 89
Behavioural disorders in Alzheimer's disease: the descriptive and predictive role of brain 18F-fluorodesoxyglucose-positron emission tomography 89
Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences 88
Cerebrospinal fluid biomarkers for dementia: A case of post-lumbar puncture epidural hematoma 86
The novel PSEN1 M84V mutation associated to frontal dysexecutive syndrome, spastic paraparesis, and cerebellar atrophy in a dominant Alzheimer's disease family 85
Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice 85
Linguistic profiles, brain metabolic patterns and rates of amyloid-β biomarker positivity in patients with mixed primary progressive aphasia 83
Neurofilament Light Chain and Intermediate HTT Alleles as Combined Biomarkers in Italian ALS Patients 83
Alzheimer's Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus 81
No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients 79
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog 77
Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia 72
Huntingtin gene intermediate alleles influence the progression from subjective cognitive decline to mild cognitive impairment: A 14-year follow-up study 69
Dual Effect of PER2 C111G Polymorphism on Cognitive Functions across Progression from Subjective Cognitive Decline to Mild Cognitive Impairment 68
A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study 68
Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia 67
CAG Repeats Within the Non-pathological Range in the HTT Gene Influence Personality Traits in Patients With Subjective Cognitive Decline: A 13-Year Follow-Up Study 66
Loss of speech and functional impairment in Alzheimer's disease-related primary progressive aphasia: predictive factors of decline 66
Impairment of episodic memory in genetic frontotemporal dementia: A genfi study 66
Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia 64
Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment 63
Incomplete penetrance in familial Alzheimer’s disease with PSEN1 Ala260Gly mutation 63
null 63
The effect of cag repeats within the non-pathological range in the htt gene on cognitive functions in patients with subjective cognitive decline and mild cognitive impairment 63
Differential early subcortical involvement in genetic FTD within the GENFI cohort 63
Cognitive functioning among patients with diabetic foot 62
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores 61
Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort 61
Gender differences in cognitive reserve: implication for subjective cognitive decline in women 61
Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia 58
Late-onset Huntington disease: An Italian cohort 58
How can elderly apolipoprotein E ε4 carriers remain free from dementia? 57
Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia 57
Data-driven staging of genetic frontotemporal dementia using multi-modal MRI 56
Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations 56
The Frequency of Intermediate Alleles in Patients with Cerebellar Phenotypes 56
The complexity of Alzheimer's disease: an evolving puzzle 55
Temporal order of clinical and biomarker changes in familial frontotemporal dementia 54
Intermediate alleles of HTT: A new pathway in longevity 52
FDG PET in the differential diagnosis of degenerative parkinsonian disorders: usefulness of voxel-based analysis in clinical practice 52
Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia 50
A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia 48
The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort 48
MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia 48
The Huntington’s Disease Gene in an Italian Cohort of Patients with Bipolar Disorder 46
GRN Missense Variants and Familial Alzheimer’s Disease: Two Case Reports 44
Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study 44
Parkinson-ALS with a novel MAPT variant 42
Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study 42
Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study 41
Comparing Cerebellar tDCS and Cerebellar tACS in Neurodegenerative Ataxias Using Wearable Sensors: A Randomized, Double-Blind, Sham-Controlled, Triple-Crossover Trial 41
Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia 40
Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort 38
Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis 35
The CBI-R detects early behavioural impairment in genetic frontotemporal dementia 35
Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales 31
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia 31
Structural brain splitting is a hallmark of Granulin-related Frontotemporal Dementia 30
Structural MRI predicts clinical progression in presymptomatic genetic frontotemporal dementia: findings from the GENetic Frontotemporal dementia Initiative cohort 30
Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia 28
Diagnostic accuracy of research criteria for prodromal frontotemporal dementia 27
Language impairment in the genetic forms of behavioural variant frontotemporal dementia 24
Matching clinical diagnosis and amyloid biomarkers in alzheimer’s disease and frontotemporal dementia 17
NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study 14
CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia 14
Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes 13
Impaired glymphatic system in genetic frontotemporal dementia: a GENFI study 13
Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results 13
Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia 13
Long Non-Coding RNA Profile in Genetic Symptomatic and Presymptomatic Frontotemporal Dementia: A GENFI Study 12
Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment 12
Prodromal language impairment in genetic frontotemporal dementia within the GENFI cohort 10
Temporal dynamics predict symptom onset and cognitive decline in familial frontotemporal dementia 8
Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia 8
Totale 6.083
Categoria #
all - tutte 24.291
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.291


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020448 0 0 0 0 77 77 90 68 60 28 38 10
2020/2021357 27 36 19 46 13 14 13 22 50 73 17 27
2021/2022315 6 7 17 12 4 24 1 42 13 20 66 103
2022/20231.161 102 233 73 93 66 205 165 56 125 6 23 14
2023/2024910 30 50 76 32 39 84 57 406 23 56 37 20
2024/20252.541 119 434 276 640 1.072 0 0 0 0 0 0 0
Totale 6.083